The End­points 11: Here are some of the most promis­ing star­tups in biotech. And Covid-19 is­n't go­ing to stop them

Quite of­ten when I high­light a pri­vate, typ­i­cal­ly ear­ly-stage biotech com­pa­ny for these an­nu­al awards, I’m asked what I look for in a com­pa­ny. How do you de­fine an End­points 11 com­pa­ny?

[Reg­is­ter for the End­points 11 event here. No cost to at­tend.]

There’s a sim­ple enough an­swer. First, I look for big ideas among the pri­vate biotechs which qual­i­fy for re­view, a swing for the fences. I’m drawn to peo­ple who are will­ing to gam­ble a chunk of their lives on new drug ideas, and in that re­gard, the stakes here are huge. Drug de­vel­op­ment is long and hard, and you could eas­i­ly be wa­ger­ing 10 or more years of your life on some­thing. So go big or go home if you aren’t plan­ning to do some­thing trans­for­ma­tive.

I want a team di­rect­ing these projects that have the tal­ent, vig­or and knowhow to make it hap­pen. Track records are key and ear­li­er fail­ures can be a big plus — de­pend­ing on how that played out.

Peo­ple are al­ways more im­por­tant than mon­ey. That’s a mantra of mine that al­ways earns quick nods in any biotech group. But mak­ing sure that a com­pa­ny has enough lu­cre to make it through to proof of con­cept, and be­yond, is al­so key to the se­lec­tion process.

Still, you’ll find com­pa­nies be­low that raised a few mil­lion to get start­ed, and biotechs that ap­pear to have found the key to Fort Knox. So it’s vari­able.

And then there’s the noise fac­tor. I want to choose com­pa­nies that can earn wide­spread recog­ni­tion for suc­cess — or make a hell of a noise if they fail. None of these com­pa­nies be­low will slink off to an anony­mous mid­night bur­ial if they fall short of vic­to­ry. They’ll make a noise heard through­out the glob­al in­dus­try, and we can all learn from it.

This year, with a pan­dem­ic rag­ing around the world, I want­ed to fo­cus more on cul­ture than par­tic­u­lar as­sets. Each of these biotechs is sort­ing out the R&D work, but I want to let the ex­ecs re­flect more on the most im­por­tant points of start­ing a com­pa­ny than the spe­cif­ic pro­gram goals in mind. Build­ing com­pa­nies these days takes some new­found in­ge­nu­ity, and it’s im­por­tant to share these points with every­one.

There are some oth­er trends you’ll see re­flect­ed in the sto­ries be­low. The in­ter­sec­tion of biotech and Big Phar­ma is tak­ing on a dif­fer­ent tone at times, with an eye to as­sem­bling large net­works of ex­perts to tack­le com­plex prob­lems. And the in­flow of bil­lions of dol­lars of fresh in­vest­ment cap­i­tal al­lows for a new breed of start­up con­spir­ing to sire trans­for­ma­tive ther­a­pies. That’s not cheap, and suc­cess is not guar­an­teed. But it is al­ways fas­ci­nat­ing.

Let me sum up here by not­ing that the biggest health­care cri­sis in 100 years has helped make biotech the place to be, for­tu­nate­ly for all of us. These com­pa­nies aren’t squan­der­ing the op­por­tu­ni­ty. And that de­serves a spe­cial shout out all on its own.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER